Showing 3721-3730 of 5268 results for "".
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat
- Analysis Reveals How Incurable Skin Cancer Resists Treatmenthttps://practicaldermatology.com/news/research-autopsies-reveals-how-incurable-skin-cancer-resists-treatment/2461637/A new analysis published in the journal Cancer Discovery reveals how some skin cancers stop responding to treatment at the end of l
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- OliX Pharmaceuticals to Start Phase 1 Trial of Androgenic Alopecia Treatmenthttps://practicaldermatology.com/news/olix-pharmaceuticals-to-start-phase-1-trial-of-androgenic-alopecia-treatment/2461626/OliX Pharmaceuticals received regulatory approval to start Phase 1 trial of androgenic alopecia treatment in Australia. The trial is a multi-center, randomized, double-blind, placebo-controlled, and single ascending dose Phase 1 study. The primary objective of the study is to evalu
- Molluscum Contagiosum Update: Two New Treatments Come Down the Pikehttps://practicaldermatology.com/news/molluscum-contagiosum-update-two-new-treatments-come-down-the-pike/2461621/Thanks to a busy pipeline, treating molluscum contagiosum may get easier. The U.S. Food and Drug Administration (FDA) accepted Novan’s New Drug Application (NDA) for Berdazimer Gel, 10.3% for the treatment of molluscum contagiosum with a Prescription Drug User Fee A
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- Metal Implants May Cause Nickel Hypersensitivityhttps://practicaldermatology.com/news/metal-implants-may-cause-nickel-hypersensitivity/2461614/Dermatologists are seeing more patients concerned about a possible skin hypersensitivity to the nickel or other metals used in implanted medical devices. Millions of people in the U.S. report having a metal allergy, and current estimates state that 10 percent of Americans will receive a
- Health Canada Approves Candela's Picoway for Melasmahttps://practicaldermatology.com/news/health-canada-approves-candelas-picoway-for-melasma/2461608/Health Canada has granted Candela’s PicoWay laser system licensing for expanded indications, including the melasma, lentigines, café au lait macules (CALMs), and Nevus of Ota. The US Food and Drug Administration gave the device a similar same nod in Oct
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage
- AI Model Helps AD Patients Diagnose Complications, Cancerhttps://practicaldermatology.com/news/ai-model-helps-ad-patients-diagnose-complications-cancer/2461606/A new artificial intelligence (AI) model can empower atopic dermatitis (AD) patients to detect complications from bacterial or viral infections and distinguish between eczema and skin lesions caused by mycosis fungoides. The AI model is detailed in a paper published in the